Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from BB Biotech ( (CH:BION) ).
BB Biotech reported a strong 2025, with its share delivering total returns of 34.2% in CHF and 53.7% in USD, clearly outperforming the Nasdaq Biotechnology Index, while net profit surged to CHF 578 million and the discount to net asset value narrowed. The company realized significant value through five portfolio company acquisitions, expanded and selectively rebalanced its holdings, refined its valuation and risk frameworks, proposed a CHF 2.25 dividend, launched a buyback program of up to 10% of shares, and announced board changes aimed at reinforcing continuity and scientific expertise for sustained, shareholder-focused growth.
The most recent analyst rating on (CH:BION) stock is a Hold with a CHF54.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.
More about BB Biotech
BB Biotech AG is a listed investment company focused on the biotechnology sector, investing primarily in innovative, clinically advanced biotech firms with differentiated assets in areas such as rare diseases, oncology and immunology. Operating with permanent capital and a globally diversified portfolio, the company seeks long-term value creation through active management, disciplined capital allocation and regular cash returns to shareholders.
Average Trading Volume: 82,415
Technical Sentiment Signal: Buy
Current Market Cap: CHF2.53B
For detailed information about BION stock, go to TipRanks’ Stock Analysis page.